| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | LGI1 Autoimmune Encephalitis; NMDAR Autoimmune Encephalitis | Active, not recruiting | Phase 3 | 2026-10-08 | | NCT05503264 |
|---|
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-06 | | NCT06790693 |
|---|
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myelin oligodendrocyte glycoprotein antibody-associated disease | Active, not recruiting | Phase 3 | 2026-09-04 | | NCT05271409 |
|---|